Fondation CentraleSupélec

The projects > Health and Quality of Life


Fondation CentraleSupélec

Sanofi, Capgemini, Ypso-Facto, GPC Bio, CEA, and CentraleSupelec announce the launch of the CALIPSO project

Origin and Philosophy of the Project

While France lags behind in the production of biopharmaceuticals and relies on imports of medical equipment, active ingredients, and drugs, stakeholders in the bioproduction sector are mobilizing to strengthen French production capacities to meet market demands.

This collective effort is necessary to improve productivity, accelerate access to new drugs at an acceptable cost, and ensure France’s competitiveness and health independence. It is a strategic issue identified by the Strategic Committee for the Health Industry and Technologies Sector.

The project details

  • #1Detailed description

    Biopharmaceuticals constitute a range of innovative drugs that rely on extracts from living biological organisms for the production of their active ingredients. Biopharmaceuticals currently represent 40% of drugs in development, giving them a crucial role in the therapeutic arsenal available to healthcare professionals.

    These innovative therapies pave the way for the emergence of new generations of vaccines and treatments for diseases that are currently incurable with drugs based on synthetic chemical active ingredients.

    The CALIPSO project revolves around three main ambitions:

    • Development and transfer of technologies to pre-industrialize a new generation of micro-sensors that will solve problems for which there is currently no effective solution worldwide.
    • Implementation of a new approach to model bioproduction processes, using pre-existing data alongside data generated by new sensors. Ultimately, the sector aims to design databases designed to integrate and store all data. These data will enable the creation of identical digital representations (“digital twins”) and processes that will in turn facilitate predictive tools to optimize certain steps of the purification process. In addition, real-time regulation systems could also be used throughout the various stages of cell culture.
    • Simultaneous exploitation of all this data (thousands per batch), driven by artificial intelligence, will accelerate the selection of molecules and their large-scale production in record time.
  • #2Objectives of the project

    The objective of the CALIPSO project (Online Process Sensors and Innovative Solutions in Bioproduction) is to offer a new approach to managing bioproduction processes by developing cutting-edge technologies and computer solutions for their exploitation.

    The use of digital tools and solutions on bioproduction development lines will increase productivity while ensuring the production of batches of very high quality.

  • #3Expected results

    The consortium aims, through CALIPSO, to have a major positive impact on public health: on one hand, the development of French bioproduction should alleviate the pressure caused by the cost of certain drugs on the French healthcare system by offering accessible alternatives to a larger number of people.

    On the other hand, the project will significantly reduce the time required for bioproduction of new remedies and vaccines.

Fondation CentraleSupélec

I support
the fundraising campaign.

Tomorrow is ambition. With your support, we will be able to welcome and educate more students to excellence, preserve our digital, industrial, and food sovereignty while positioning ourselves as leaders in health and quality of life.